Table 1 Demographic and clinical baseline characteristics of 99 children with intra-thoracic TB and samples analyzed for transcriptional biomarkers (dcRT-MLPA).

From: BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome

Baseline characteristics

Distribution

Sociodemographics and medical history

 Gender

Male (n)

45

 Age

mean age in months (St.dev)

107,8 (46,0)

 

≤5 years (n)

16

 

>5 to ≤10 years (n)

40

 

>10 to 16 years (n)

43

 Known contact with TB patient (n)

35

 BCG vaccination

 

Yes (n)

82

 

No (n)

16

 

Not known (n)

1

Symptoms

 Cough ≥2 weeks (n)

63

 Fever (n)

77

 Weight loss (n)

74

 Loss of appetite (n)

74

Anthropometric data

 Body Mass Index Z-score, mean (St.dev)

−2,28 (1,46)

 Weight-for-age Z-score, mean (St.dev)

−2,54 (1,68)

Diagnosis and treatment

 

 Smear positivityˇ (n)

13

 Mtb-culture positive° (n)

41

 NTM culture positivea (n)

7

 Finding on Chest X-ray

 
 

uncomplicated LN disease (n)

17

 

LN disease with collapse (n)

2

 

progressive primary disease (n)

49

 

primary pulmonary complex (n)

11

 

miliary TB (n)

1

 

pleural effusion (n)

8

 

cavitation disease (n)

10

 

calcification (n)

1

 Lymph node swelling (n)

19

 Tuberculin Skin Test

 
 

mean in mm (St.dev)

15,1 (8,1)

 

≥10 mm (n)

96

 QuantiFERON Gold In-tube

 

Positive (n)

76

 

Negative (n)

22

 

Indeterminate (n)

1

 Anti-tuberculosis treatment

 

Category 1 b (n)

75

 

Category 3 c (n)

24

 Micronutrient supplement

 

Micronutrients and Zinc (n)

25

 

Micronutrients (n)

21

 

Zinc (n)

26

 

Placebo (n)

27

  1. Of 2 induced sputum samples and 2 gastric aspirate samples taken on 2 consecutive days at least ˇone specimen positive for acid-fast bacilli, °one culture samples with growth of Mycobacterium tuberculosis oraNon-tuberculous mycobacteria. b2 months with isoniazid, rifampicin, pyrazinamide and etambuthol followed by 4 months of isoniazid, rifampicin. c2 months with isoniazid, rifampicin and pyrazinamide followed by 4 months of 2 drugs.